

Dated: February 10, 1995.

Louis H. Blair,

Executive Secretary.

[FR Doc. 95-4091 Filed 2-17-95; 8:45 am]

BILLING CODE BOAC-95001-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 94N-0357]

Surveillance System for Antimicrobial Resistance; Public Hearing; Reopening of Comment Period

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; reopening of comment period.

SUMMARY: The Food and Drug Administration (FDA) is reopening to April 1, 1995, the comment period for the notice of public hearing regarding approaches to surveillance for the development of bacterial resistance to human and animal antimicrobial drugs, which published in the **Federal Register** of October 14, 1994 (59 FR 52168). Interested persons were given until February 1, 1995, to submit comments. FDA is taking this action to provide interested persons with an opportunity to comment on submissions received after the public hearing.

DATES: Submit written comments by April 1, 1995.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with docket number found in brackets in the heading of this document. Received comments may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday. Transcripts of the November 9 and 10, 1994, hearing are available for review at the Dockets Management Branch (address above).

FOR FURTHER INFORMATION CONTACT: Ermona McGoodwin, Center for Drug Evaluation and Research (HFD-9), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5455.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of October 14, 1994 (59 FR 52168), FDA announced that it would be holding a public hearing November 9 and 10, 1994, on

surveillance systems for antimicrobial resistance. Interested persons were given until February 1, 1995, to submit comments. The purpose of the hearing was to solicit information from, and the views of, interested persons, including scientists, professional groups, and consumers, on the issues and concerns relating to approaches for regulatory purposes to surveillance for the development of bacterial resistance to antibacterial agents used in humans and in animals. This hearing was held in response to a recommendation for improved surveillance for the development of antimicrobial resistance in both animals and humans as discussed at the May 11 and 12, 1994, joint meeting of FDA's Anti-Infective Drugs Advisory Committee and the Veterinary Medicine Advisory Committee (see the **Federal Register** of April 15, 1994, (59 FR 18136 at 18137)).

FDA is actively seeking the views of professional and consumer groups regarding the implications of an animal and human bacterial resistance monitoring system for regulatory purposes on their constituent populations. To permit time for all interested persons to comment on submissions received after the public hearing, the administrative record of the hearing will remain open until April 1, 1995. Persons who wish to provide additional materials for consideration should file these materials with the Dockets Management Branch (address above) by April 1, 1995.

Dated: February 14, 1995.

William B. Schultz,

Deputy Commissioner for Policy.

[FR Doc. 95-4213 Filed 2-17-95; 8:45 am]

BILLING CODE 4160-01-F

National Institutes of Health

National Institute of Environmental Health Sciences; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting:

Name of Committee: Environmental Health Sciences Review Committee

Date: March 27-29, 1995.

Time: 8:30 a.m. to Adjournment.

Place: National Institute of Environmental Health Sciences, Building 101 Conference Room, South Campus, Research Triangle Park, North Carolina.

Contact Person: Dr. Ethel Jackson, Scientific Review Administrator, P.O. Box 12233, Research Triangle Park, NC 27709, (919) 541-7826.

Purpose: To review and evaluate grant applications.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program Nos. 93.113, Biological Response to Environmental Health Hazards; 93.114, Applied Toxicological Research and Testing; 93.115, Biometry and Risk Estimation; 93.894, Research and Manpower Development, National Institutes of Health.)

Dated: February 14, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95-4114 Filed 2-17-95; 8:45 am]

BILLING CODE 4140-01-M

National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Initial Review Group (IRG) meeting:

Name of IRG: Heart, Lung, and Blood Program Project Review Committee.

Date: March 23-24, 1995.

Time: 8:00 a.m.

Place: Holiday Inn Chevy Chase, Chevy Chase, Maryland.

Contact Person: Dr. Jeffrey Hurst, 5333 Westbard Avenue, Room 555, Bethesda, Maryland 20892, (301) 594-7418.

Purpose/Agenda: To review and evaluate grant applications.

The meeting will be closed in accordance with the provisions set forth in sec. 552(b)(c)(4) and 552(c)(6), Title 5, U.S.C. Applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health.)

Dated: February 14, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95-4112 Filed 2-17-95; 8:45 am]

BILLING CODE 4140-01-M